iRDBMS Reveals Latest Research on TPD Anticancer Drug 'IL2106' at International Conference

Irid BMS, a subsidiary of Ildong Pharmaceutical Group, announced on the 27th that it revealed the latest research results related to IL2106, a targeted protein degradation (TPD) therapeutic agent under development, at the '2024 European Society for Medical Oncology Targeted Anticancer Therapy Conference (ESMO TAT 2024)' held in Paris, France from the 26th to 28th (local time).

IRID BMS Logo
[Photo by IRID BMS]

IL2106 is a molecular glue in the TPD therapeutic field independently developed by Irid BMS. It targets cyclin-dependent kinase (CDK) 12, a protein that regulates the expression of genes associated with cancer development. CDK12 is known to form a complex with cyclin K, a protein involved in cell cycle regulation, affecting the growth and metastasis of refractory cancer cells.

The research results showed that IL2106 binds to CDK12 to effectively inhibit its activity and selectively degrades cyclin K by utilizing the body's protein degradation mechanism.

In the poster presentation, IL2106 strongly suppressed the growth of refractory cancers such as triple-negative breast cancer and human epidermal growth factor receptor (HER)2-negative gastric cancer cells through targeted protein degradation in in vitro experiments.

In a triple-negative breast cancer model study using experimental mice, effective degradation of target proteins within tumors was observed in the group orally administered IL2106, and animal models transplanted with triple-negative breast cancer and metastatic HER2-negative gastric cancer showed a significant reduction in tumor size and cancer cell metastasis rate in the IL2106 treatment group compared to the control group.

An Irid BMS official stated, "IL2106 is a drug that eliminates causative proteins of specific cancers, enabling fundamental treatment and is expected to overcome resistance issues," adding, "As an oral therapeutic agent, it has differentiating factors in terms of competitiveness and ease of use upon commercialization."